Sign in
Taking peoplePhase 2

Ayahuasca, Esketamine and PTSD

Key facts

Who runs it
University of Sao Paulo
Where
Brazil1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
10 people, planned
Started
20 Dec 2025
Planned end
Jul 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ayahuasca
  • Esketamine
Record updated
5 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • posttraumatic stress disorder

Who cannot take part

  • psychiatric and other medical comorbidities

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in Brazil.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.

The 2 groups in the trial

  • AyahuascaTreatment being tested

    oral ayahuasca

  • esketamineExisting treatment, for comparison

    oral esketamine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study
Criteria questions
Built from NCT07317206, who can take part
Record updated
5 January 2026